Jellagen boosted by £3.8m in funding

3rd May 2018

Jellagen, Welsh marine biotechnology firm and Newable client have received £3.8m in funding to accelerate sales of its next-generation jellyfish-based medicine.

A Welsh marine biotechnology firm has received £3.8m in funding to accelerate sales of its next-generation jellyfish-based medicine.

Cardiff-based Jellagen is the first commercial manufacturer of jellyfish collagen, which is a a substance that can be used for wound care and regenerative medicine.

The firm, founded in 2013, has closed a £3.8m funding round and will use the investment to accelerate sales of its products into the cell culture market and regenerative medicine, whilst growing its specialist management team and strengthening its intellectual property portfolio.

"Jellyfish represent a source of ‘next generation’ collagen with diverse application potential, including for research in the medical, biotech and pharmaceutical markets," said Professor Andrew Mearns Spragg, founder & CEO of Jellagen.

"Because of the evolutionary lineage of jellyfish collagen, it presents the market with a valuable alternative to more conventional sources."

The first range of products developed by the firm are cell culture reagents, which are used to grow stem cells. The firm also plans to produce medical devices engineered around jellyfish collagen.

The funding round was led by Newable Private Investing, the Development Bank of Wales, and angel investors.

"Jellagen is a great example of an exciting Welsh business that’s pushing technological boundaries," said Carmine Circelli, technology ventures investment executive at Development Bank of Wales.

"Both this funding and their recent certification show that the business has real potential to push further into the cell culture market.

"Supporting businesses like Jellagen is at the core of our mission, and we look forward to hearing of their future success."

For more information on Funds, visit https://investment.newable.co.uk/.

 

 Newable Ventures Limited (FRN 795277) is an Appointed Representative of Larpent Newton & Co Ltd. Larpent Newton & Co Ltd is authorised and regulated by the Financial Conduct Authority, FRN 141275.
Neither Newable Capital Limited nor Newable Private Investing Limited are Authorised and Regulated by the Financial Conduct Authority. Risk warning: Your capital is at risk. Investing in early stage companies involves risks including loss of capital, illiquidity, lack of dividends and dilution. Newable Ventures Limited does not give tax or investment advice.
The availability of tax relief depends on individual investors’ circumstances, and on investee companies’ qualifying status, both of which may be subject to change. If you are in doubt about eligibility for tax reliefs or the tax treatment of your investment, you should seek independent tax advice.